Dishman Carbogen Amcis Ltd Q1FY26 – From Vitamin D3 to ADCs, 950 PhDs and Still a 2% ROCE Soap Opera
1. At a Glance
Dishman Carbogen Amcis Ltd (DCAL), aka the pharma-outsourcing buffet serving 250 global clients, trades at ₹281 with a market cap of ₹4,410 Cr. The stock has been on a steroid cycle – up 53% in 1 year – but the financials look like a patient still in ICU. P/E is a spicy 37x, while ROE is actually negative (-0.3%). Debt sits at ₹2,389 Cr, and despite 25 plants across India, Switzerland, UK, France, and China, their Return on Assets is a princely -0.19%. Sales TTM: ₹2,896 Cr. PAT TTM: ₹119 Cr. Operating margin: 20%. Market loves the export-heavy story (90% of sales abroad), but investors quietly whisper – why is my money tied up in a 2.4% ROCE stock?
2. Introduction
Let’s be clear: Dishman is that overqualified cousin – 950 scientists, 50% of them PhDs, R&D labs sprinkled across continents, FDA/PMDA/EDQM stamps proudly displayed – but still scoring below average in finance class.
Founded on the CRAMS model (Contract Research and Manufacturing Services), DCAL helps pharma innovators from early-stage drug research to late-stage commercialization. Sounds fancy. Yet, in India, when you tell someone “I work in CRAMS,” they’ll assume you’re helping cousins cram before IIT entrance.
What makes them unique? Two words: highly potent APIs. They operate one of Asia’s largest high-potency (HiPo) facilities in Bavla, Gujarat, where employees probably wear more layers of protection than NASA astronauts. On the side, they churn out Vitamin D3, disinfectants, and specialty chemicals – basically ensuring they stay relevant even if drug discovery slows down.
But here’s the irony: despite such technical depth, financial returns remain wafer-thin. This company could cure cancer in Switzerland, yet the stock chart in India still gives investors hypertension.
3. Business Model – WTF Do They Even Do?
Think of Dishman as a premium restaurant for global pharma: clients bring raw recipes (molecules), Dishman cooks them in their R&D kitchens, tests them, scales them up, and plates them for clinical trials or commercial batches.
CRAMS (88% of revenue):
Carbogen Amcis (Switzerland): White-lab-coat services for drug innovators, specializing in potent and non-potent APIs, injectables, and antibody-drug conjugates (ADCs). This is the Michelin-star section.
Dishman India: Handles scale-up and manufacturing muscle – essentially the thali section that feeds the whole industry.
Marketable Molecules (12% of revenue):
Vitamin D3 (1,000 MT capacity, serving pharma, nutrition, even cow-feed).
Specialty Chemicals (Wittig reagents, quats, lanolin derivatives – stuff only chemistry nerds get excited about).
Disinfectants & APIs (for when you need both to kill germs and balance P&L).
Question: Would you pay a 37x P/E for a company whose side hustle is Vitamin D3 powder, while the main act is servicing mid-tier European pharma?
4. Financials Overview
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹708 Cr
₹524 Cr
₹716 Cr
35.2%
-1.1%
EBITDA
₹141 Cr
₹29 Cr
₹153 Cr
386%
-7.8%
PAT
₹23 Cr
-₹78 Cr
₹43 Cr
Turned Profitable
-46%
EPS (₹)
1.49
-4.95
2.75
NA
-45.8%
Comment: Topline growing well, but profitability swings like Virat Kohli’s moods on Twitter. Annualised EPS ~₹6, matching actual TTM EPS. P/E math checks out, but valuation still looks like Switzerland pricing with Bavla returns.
5. Valuation Discussion – Fair Value Range Only
P/E Method: EPS ~₹6.65. Apply a realistic 20–25x (given global exposure, but low ROE). Fair Value Range: ₹133–₹166.
EV/EBITDA Method: EV = ₹6,291 Cr. EBITDA TTM = ₹581 Cr. EV/EBITDA = ~10.8x. Global peers trade 12–15x. Fair Value Range: ₹11–₹14x EBITDA → Equity Value = ₹6,500–₹8,200 Cr → Per Share = ₹370–₹465.
DCF (ballpark): Assume revenue CAGR 10%, margin expansion to 22%, WACC 12%. Intrinsic band = ₹250–₹400.
🎤 Disclaimer: This fair value range is for educational purposes only and not investment advice.
6. What’s Cooking – News, Triggers, Drama
FDA Clean Chit (Jun’25): Naroda unit cleared by US FDA with zero observations. That’s like clearing CBSE exams without a single red line in the answer sheet.
Promoter Shock (May’25): Chairman & promoter Shri Janmejay R. Vyas passed away. Promoter holding remains intact at 59.3%, but leadership transition risk looms.
China License (Apr’25): Carbogen Amcis Shanghai bagged a drug manufacturing license. Entry into Chinese pharma – translation: welcome to world’s toughest tuition class.
Capex & Fund Raise (FY26): Board approved ₹1,000 Cr fund raise to
